[Splendours and miseries of the benefit-risk ratio].
Dupuy
A
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D056486:Chemical and Drug Induced Liver Injury / Q000453:epidemiology; D005062:European Union; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D007600:Judgment; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology; D011336:Probability; D011565:Psoriasis / Q000188:drug therapy; D018570:Risk Assessment; D056737:Safety-Based Drug Withdrawals
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab